Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

UPDATE 1-Valeant cuts revenue forecast; makes progress on debt repayment

Published 2017-08-08, 07:42 a/m
© Reuters.  UPDATE 1-Valeant cuts revenue forecast; makes progress on debt repayment
PSON
-
BHC
-

(Adds details)

Aug 8 (Reuters) - Canada's Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.N VRX.TO cut its full-year revenue forecast, even as it reported a better-than-expected quarterly profit and said it expects to repay more than $5 billion in debt by February.

Since taking the helm in April 2016, Joseph Papa has been trying to rebuild the company's business and regain investor confidence after a flurry of investigations into its accounting and pricing practices.

One of Papa's biggest challenges has been to cut the company's towering debt, which ballooned to nearly $30 billion following a spate of deal-making under former CEO Mike Pearson (LON:PSON).

The maker of Bausch + Lomb contact lenses said on Tuesday it now expects revenue of $8.70 billion to $8.90 billion for the full year, down from its previous forecast of $8.90 billion to $9.10 billion.

Last month, the drugmaker paid down $811 million of debt with proceeds from the sale of its cancer treatment unit Dendreon Pharmaceuticals, and agreed to sell its Obagi Medical Products business for $190 million. In June, Valeant agreed to sell its iNova Pharmaceuticals business for $930 million. which also maintained its 2017 forecast for adjusted earnings before interest, tax, depreciation and amortization, said it had long-term debt of about $28.5 billion as of June 30.

The company said it expected to pay down more than $5 billion in debt from divestiture proceeds and free cash flow before February 2018.

Excluding items, the Laval, Quebec-based company earned $1.05 per share, ahead of the average analyst estimate of 94 cents, according to Thomson Reuters I/B/E/S.

Revenue fell 7.8 percent to $2.23 billion in the second quarter ended June 30, hurt by declines in volume and pricing of its generic and neurology products.

Net loss attributable to Valeant narrowed to $38 million from $302 million, a year earlier. The decrease in net loss was mainly due to income tax gains and increase in operating income, the company said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.